114 related articles for article (PubMed ID: 16050267)
1. Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs.
Sanguinetti MC; Chen J; Fernandez D; Kamiya K; Mitcheson J; Sanchez-Chapula JA
Novartis Found Symp; 2005; 266():159-66; discussion 166-70. PubMed ID: 16050267
[TBL] [Abstract][Full Text] [Related]
2. Structural determinants for high-affinity block of hERG potassium channels.
Mitcheson J; Perry M; Stansfeld P; Sanguinetti MC; Witchel H; Hancox J
Novartis Found Symp; 2005; 266():136-50; discussion 150-8. PubMed ID: 16050266
[TBL] [Abstract][Full Text] [Related]
3. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
4. Structural determinants of HERG channel block by clofilium and ibutilide.
Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J
Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical features of the HERG channel drug binding site.
Fernandez D; Ghanta A; Kauffman GW; Sanguinetti MC
J Biol Chem; 2004 Mar; 279(11):10120-7. PubMed ID: 14699101
[TBL] [Abstract][Full Text] [Related]
6. A structural basis for drug-induced long QT syndrome.
Mitcheson JS; Chen J; Lin M; Culberson C; Sanguinetti MC
Proc Natl Acad Sci U S A; 2000 Oct; 97(22):12329-33. PubMed ID: 11005845
[TBL] [Abstract][Full Text] [Related]
7. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels.
Chen J; Seebohm G; Sanguinetti MC
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12461-6. PubMed ID: 12209010
[TBL] [Abstract][Full Text] [Related]
8. HERG block, QT liability and sudden cardiac death.
Brown AM
Novartis Found Symp; 2005; 266():118-31; discussion 131-5, 155-8. PubMed ID: 16050265
[TBL] [Abstract][Full Text] [Related]
9. Molecular determinants of HERG channel block.
Kamiya K; Niwa R; Mitcheson JS; Sanguinetti MC
Mol Pharmacol; 2006 May; 69(5):1709-16. PubMed ID: 16474003
[TBL] [Abstract][Full Text] [Related]
10. Intracellular K+ is required for the inactivation-induced high-affinity binding of cisapride to HERG channels.
Lin J; Guo J; Gang H; Wojciechowski P; Wigle JT; Zhang S
Mol Pharmacol; 2005 Sep; 68(3):855-65. PubMed ID: 15967876
[TBL] [Abstract][Full Text] [Related]
11. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.
Ridley JM; Milnes JT; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2004 Dec; 325(3):883-91. PubMed ID: 15541373
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.
Alexandrou AJ; Duncan RS; Sullivan A; Hancox JC; Leishman DJ; Witchel HJ; Leaney JL
Br J Pharmacol; 2006 Apr; 147(8):905-16. PubMed ID: 16474415
[TBL] [Abstract][Full Text] [Related]
13. Molecular determinants of high-affinity drug binding to HERG channels.
Mitcheson JS; Perry MD
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):667-74. PubMed ID: 14579516
[TBL] [Abstract][Full Text] [Related]
14. Drugs, hERG and sudden death.
Brown AM
Cell Calcium; 2004 Jun; 35(6):543-7. PubMed ID: 15110144
[TBL] [Abstract][Full Text] [Related]
15. Blockade of HERG cardiac K+ current by antifungal drug miconazole.
Kikuchi K; Nagatomo T; Abe H; Kawakami K; Duff HJ; Makielski JC; January CT; Nakashima Y
Br J Pharmacol; 2005 Mar; 144(6):840-8. PubMed ID: 15778703
[TBL] [Abstract][Full Text] [Related]
16. Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K; Niwa R; Morishima M; Honjo H; Sanguinetti MC
J Pharmacol Sci; 2008 Nov; 108(3):301-7. PubMed ID: 18987434
[TBL] [Abstract][Full Text] [Related]
17. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
18. In silico modelling--pharmacophores and hERG channel models.
Recanatini M; Cavalli A; Masetti M
Novartis Found Symp; 2005; 266():171-81; discussion 181-5. PubMed ID: 16050268
[TBL] [Abstract][Full Text] [Related]
19. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
20. Effect of S5P alpha-helix charge mutants on inactivation of hERG K+ channels.
Clarke CE; Hill AP; Zhao J; Kondo M; Subbiah RN; Campbell TJ; Vandenberg JI
J Physiol; 2006 Jun; 573(Pt 2):291-304. PubMed ID: 16556651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
